Commercial Insight: Pain Market Overview

Content

• About Datamonitor Healthcare
  • About The Central Nervous System Pharmaceutical Analysis Team
• Chapter 1 Executive Summary
  • Strategic Scoping And Focus
  • Datamonitor Insight Into The Disease Market
  • Related Reports
  • Upcoming Related Reports
• Chapter 2 Market Definition
  • Market Definition For This Report
  • Disease Definition
  • Overview Of Pain-Drug Classes
  • M1a - Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
  • N1a - General Anesthetics
  • N1b - Local Anesthetics
  • N2a - Narcotic Analgesics
  • N2b - Non-Narcotic Analgesics
  • Non-Traditional Analgesics
• Chapter 3 Market Overview
  • Current Market Assessment
  • Sales By Region
  • Pain Market Totaled $24.3 Billion In 2007
  • 5eu Was The Key Growth Market For Pain In 2004-07
  • Pain Market Is A Huge Volume Market
  • Despite Recording Negative Sales Value Growth, The Us Pain Market Increased By Volume
  • Sales By Class
  • N2a Narcotic Analgesic Class Accounts For The Largest Proportion Of The Pain Market Value
  • N2b Non-Narcotic Analgesic Class Accounts For Over Half Of All Pain Market Prescription Volume
  • Sales By Hospital Or Retail
  • France And Italy Have The Greatest Proportion Of Sales Originating From The Hospital Sector
  • General Anesthetics Sales Originate Predominantly From The Hospital Setting
  • Sales By Branded And Unbranded Drugs
  • Unbranded Drugs Have Accounted For The Majority Of The Pain Market Value Since 2005
  • Japan Pain Market Is By Far The Least Genericized
  • Unbranded Products Dominate The Traditional Analgesic Classes
  • Sales By Delivery Method
  • Sales Of Solid Oral Products Dominate Pain-Drug Prescriptions
  • Higher Priced Parenteral And 'Other' Systemic Formulations Account For A Greater Proportion Of The Pain Market Sales Value
  • Rest Of World Snapshot
  • Current Market Assessment
  • Rest Of The World Pain Market Is Growing Faster Than The Seven Major Markets
  • Rest Of World Is Larger Than The Combined 5eu And Japan Regions And Accounts For One-Third Of Total Global Pain Market By Value
  • Canada Represents The Largest Of The Small And Emerging Pain Markets, Brazil Is A Close Second
  • In South America, Brazil, Peru And Venezuela Are All Growing At Over 20% A Year
  • With Retail Sales Only, China Represents The Strongest Growing Pacific Rim Pain Market Over 2004-07
  • Future Market Assessment
  • Sales By Region
  • The Us Will Be More Susceptible To Growth Deviations As The 5eu Market Is Expected To Show Steady Yearly Growth
  • Sales By Class
  • Market To Maintain Recent Positive Turnaround In Sales
  • Non-Traditional Analgesic Class To Claim A Greater Share Of The Pain Market
• Chapter 4 Opportunities And Threats
  • Pain Market Opportunities
  • Underserved Pain Indications Continue To Provide Significant Opportunities
  • Fibromyalgia - Fda Approvals Further Validate Condition But Misdiagnosis Remains An Issue
  • Neuropathic Pain - Improved Efficacy Rather Than Side-Effect Profile Is Key To Driving Commercial Success
  • Cancer Pain - Variety Of Co-Morbidities And Types Of Pain Experienced Leave Room For Great Treatment Improvement
  • Breakthrough Pain In Non-Malignant Diseases
  • Back Pain
  • Opportunities Exist For Reformulations In The Mature Opioids Market
  • Requirement For Anti-Abuse Technologies Sees The Us Fda Designating Two Recently Filed Ndas With Priority Reviews
  • Rapid-Onset Developments Focus On Fentanyl
  • Non-Traditional Analgesic Classes
  • Physicians Are Now Turning To Alternative Analgesics Amid Concerns Over Nsaid And Opioid Use
  • Pain Market Threats
  • Stigma Attached To Opioid Abuse Should Not Influence Guidelines In Such A Way That Restricts Access
  • State Pain Policies Must Value Opioid Effectiveness
  • Pharmacovigilance Requirements Leads To More Rigorous Post-Marketing Regulations
  • Risk Evaluation And Mitigation Strategy (Rems) Safety Plan Deemed Essential For Certain Fda Approved Fentanyl Products
  • Cephalon Asked To Address Fentora Risk Management Program Before Potential Approval For Non-Cancer Breakthrough Pain
• Chapter 5 Brand Dynamics
  • Overview Of Competitive Landscape
  • Leading 10 Brands In The Pain Market
  • Celebrex And Oxycontin - Only Pain Brands To Achieve Blockbuster Status In 2007
  • Duragesic And Actiq - Two Branded Fentanyl Formulations Succumb To Genericization
  • Lyrica And Cymbalta - Non-Traditional Analgesic Brands Show Strongest 4-Year Growth
  • Marketing Strategies For The Leading Brands
  • Promotional Spend
  • Sponsorship And Public Awareness Campaigns
  • Direct-To-Consumer Advertising
  • M1a Class Leader: Celebrex (Celecoxib, Pfizer)
  • Drug Profile
  • Celebrex Sales Are Largely Derived From The Us Market
  • Increased Promotional Efforts In The Us Sees Sales Rebound
  • Celebrex Reserved For Second-Line Osteoarthritis Therapy After Acetaminophen Or A Topical Nsaid
  • Swot Analysis
  • Strengths - Broad Indication Coverage And Us Patent Protection To Drive Mid-Term Sales Growth
  • Weaknesses - Cardiovascular Warnings On Label Document Potential Risks With Celebrex Use
  • Opportunities - Japanese Launch Opens Up New Market Opportunities
  • Threats - Pipeline Drugs To Provide Major Market Threat
  • N1a Class Leader: Sevorane (Sevoflurane, Abbott)
  • Drug Profile
  • Availability Of Baxter's Generic Sevoflurane Versions Results In Declining Yearly Sales
  • Swot Analysis
  • Strengths - Remains Inhaled General Anesthetic Gold Standard After More Than 15 Years On The Market
  • Weaknesses - Level Of Genericization Will Increase With Major Patents Expired
  • N1b Class Leader: Lidoderm (Lidocaine 5% Patch, Endo)
  • Drug Profile
• 2007 European Roll-Out Comes 8 Years After Us Launch
  • Swot Analysis
  • Strengths - Remains First And Only Of Its Kind Resulting In Strong Brand Loyalty
  • Weaknesses - Although Rare And Mild In Nature Lidoderm Can Cause Local Allergic Reactions
  • Opportunities - Eu Launch As Versatis Should Maintain Strong Historical Sales Growth
  • Threats - Uncertainty Over Strength Of Us Patents Could See Challengers Emerge
  • N2a Class Leader: Oxycontin (Oxycodone Hcl Controlled-Release, Purdue)
  • Drug Profile
  • Extensive Genericization Has Hit Sales Over The Last 4 Years
  • Swot Analysis
  • Strengths - Purdue Has Successfully Reinstated Oxycontin's Key Patents
  • Weaknesses - Abuse Potential Limits Oxycontin's Patient Potential
  • Opportunities - Launch Of New Dosages Provides More Options For Abuse-Prone Patients
  • Threats - Imminent Launch Of Abuse Deterrent Oxycodone Formulations Will Pressurize Oxycontin
  • N2b Class Leader: Efferalgan (Acetaminophen, Bristol-Myers Squibb)
  • Drug Profile
  • Non-Traditional Analgesic Class Leader: Lyrica (Pregabalin, Pfizer)
  • Drug Profile
  • Sales From Pain Indications Accounted For Over 60% Of Lyrica's 2007 Total
  • Swot Analysis
  • Strengths - Broad Neuropathic Pain Indications And Most Recent Fibromyalgia Approval To Drive Future Growth
  • Weaknesses - Schedule V Classification Increases Complexity Of Prescribing
  • Opportunities - Lyrica Has Yet To Be Launched In Japan
  • Threats - Approval Of Additional Drugs For Fibromyalgia Will Provide Stiff Competition In This Young And Growing Market
• Chapter 6 Key Developers
  • Strategic Overview
  • Despite A Significant Decline In Its Franchise, Pfizer Continues Be The Driving Force In The Pain Market
  • Generics Companies Have Prospered In The Pain Market
  • Trends In Corporate Strategy
  • Only Half Of The Leading 10 Pain Market Companies Are Actively Looking To Further Enhance Their Pain Franchise Offerings
  • Big Pharma Seeks Out Novel Developments While Specialist Companies Focus On Reformulations
  • Recent Strategic Partnerships/Deals
  • Licensing Deals Will Remain An Important Strategy To Companies Of All Sizes In The Pain Market
  • Big Pharma Market Leader - Pfizer
  • Unearthing Unchartered Pain Indications Continues To Reap Rewards
  • Increased Celebrex Investment Set To Drive Future Growth
  • Pfizer - The Pioneer In Neuropathic Pain And Now Fibromyalgia
  • Pfizer Identifies Pain To Be A 'High-Potential Disease Area'
  • Late-Stage Developments Show Desire To Maintain Investment In Well-Established Pain Franchise
  • Specialist Pain Company - Endo
  • Endo Prospers On Lidoderm's Success
  • Recently Established Opana Franchise Set For Steady Growth
  • Research And Development Review Sees Endo Discontinue Development Of Two Late-Stage Pain Products
  • In-Licensing Remains Key In Endo's Refocused Pipeline
  • Leading Generics Company Presence - Teva
  • The Exploitation Of Major Pain Brands Proves A Lucrative Strategy For Teva
  • Reinstated Oxycontin Patent To Hurt Teva From 2008
  • Challenges To Celebrex's Patents Appear To Be Unsuccessful
  • Key Emerging Companies - King Pharmaceuticals And Pain Therapeutics
  • Strategic Alliance Plays A Significant Part In King Pharmaceuticals And Pain Therapeutics Emergence As Key Players In The Pain Market
  • Partnership Marries Drug Development Capabilities With Commercial Expertise
  • Remoxy's Anti-Abuse Potential To Fulfill A Significant Market Opportunity
  • Potential Alpharma Takeover Shows King Pharmaceuticals's Intention To Further Shift Focus To The Pain Market
  • Oxytrex Shows Pain Therapeutics' Development Strength And Provides Another Strong Out-Licensing Opportunity
  • Bibliography
  • Journal Papers
  • Websites
  • Datamonitor Reports
  • Appendix A - Market Assumptions
  • Data Definitions, Limitations And Assumptions
  • Standard Units
  • Japanese Market Data
  • Rest Of World
  • Forecast Methodology
  • Important Information Specifically For This Report
  • Appendix B
  • Report Methodology
  • About Datamonitor
  • About Datamonitor Healthcare
  • About The Central Nervous System Analysis Team
  • Disclaimer
• List Of Tables
  • Table 1: Pain Market Sales Value By Region ($M) Across The Seven Major Markets (7mm), 2004-07
  • Table 2: Pain Market Sales Volume By Region ($M) Across The Seven Major Markets, 2004-07
  • Table 3: Pain Market Sales Value By Class Across The Seven Major Markets ($M), 2004-07
  • Table 4: Pain Market Sales Volume By Class Across The Seven Major Markets ($M), 2004-07
  • Table 5: Summary Of Opportunities And Threats In The Seven Major Market Pain Market, 2008
  • Table 6: Epidemiology Surveys Of Cancer Pain
  • Table 7: Epidemiology Surveys Of Breakthrough Pain In Cancer Patients
  • Table 8: Epidemiology Surveys Of Low Back Pain
  • Table 9: Top 10 Pain Brands By Seven Major Market Revenues ($M), 2004-07
  • Table 10: Marketing Strategies Employed By The Companies Behind The Top Three Pain Market Brands, 2008
  • Table 11: Celebrex - Drug Profile, 2008
  • Table 12: Sevorane - Drug Profile, 2008
  • Table 13: Lidoderm - Drug Profile, 2008
  • Table 14: Oxycontin - Drug Profile, 2008
  • Table 15: Lyrica - Drug Profile, 2008
  • Table 16: Top 10 Pain Market Companies By Seven Major Market Revenues ($M), 2004-07
  • Table 17: Strategic Importance Of Pain Market Drugs To The Leading Pain Market Companies, 2008
  • Table 18: Key Strategic Deals And Events In The Pain Market, 2008
  • Table 19: Pfizer's Pain Market Portfolio Overview, 2004-07
  • Table 20: Pfizer's Late-Stage (Phase Ii Onwards) Pain Pipeline, 2008
  • Table 21: Endo's Pain Market Portfolio Overview, 2004-07
  • Table 22: Endo's Pain Pipeline, 2008
  • Table 23: Teva's Pain Drug Portfolio Overview, 2004-07
• List Of Figures
  • Figure 1: Pain Market Sales Value In The Us, 5eu And Japan ($ Billion), 2004-07
  • Figure 2: Sales Value Performance Of The Us, 5eu And Japan Pain Markets ($M), 2004-07
  • Figure 3: Pain Market Sales Volume In The Us, 5eu And Japan (Ims Standard Units [Sus] Sold), 2004-07
  • Figure 4: Sales Volume Performance Of The Us, 5eu And Japan Pain Markets (Ims Standard Units [Sus] Sold), 2004-07
  • Figure 5: Sales Value Performance Of The Seven Major Market Pain Market By Class ($M), 2004-07
  • Figure 6: Sales Volume (Sus M) Performance Of The Seven Major Market Pain Market By Class, 2004-07
  • Figure 7: Pain Market Volume And Value Sales By Retail And Hospital Distribution Channel In The Us And 5eu Countries, 2007
  • Figure 8: Pain Market Volume And Value Sales In Terms Of Retail And Hospital Origin In The Us And 5eu By Class, 2007
  • Figure 9: Branded And Unbranded Sales Value Of The Pain Market Across The Seven Major Markets ($M), 2004-07
  • Figure 10: Branded And Unbranded Pain Market Volume And Value Sales In The Us, 5eu And Japan, 2007
  • Figure 11: Branded And Unbranded Pain Market Volume And Value Sales In The Seven Major Markets By Class, 2007
  • Figure 12: Seven Major Market Pain Market Sales Volume (Ims Standard Units Sold) By Delivery Method, 2007
  • Figure 13: Seven Major Market Pain Market Sales Value Dynamics By Delivery Method, 2007
  • Figure 14: Pain Market Sales Value ($ Billion) And Volume (Ims Standard Units [Sus]) In The Rest Of The World, 2004-07
  • Figure 15: Rest Of World Versus Seven Major Market Sales Split In The Pain Market ($M), 2007
  • Figure 16: Sales Value Of The Largest 10 Small And Emerging Pain Markets, 2004-07
  • Figure 17: Pain Market Sales Value In South America ($M), 2004-07
  • Figure 18: Pain Market Sales Value Dynamics In The Pacific Rim ($M), 2004-07
  • Figure 19: Pain Market Historic (2004-07) And Datamonitor Forecast (2008-2017) Sales By Region Across The Seven Major Markets
  • Figure 20: Pain Market Historic (2004-07) And Datamonitor Forecast (2008-2017) Sales By Class Across The Seven Major Market
  • Figure 21: Market Value Share Of Pain Market Drug Classes In The Seven Major Markets ($ Billion), 2007 Versus 2017
  • Figure 22: Top 10 Pain Brands By Seven Major Market Revenues ($M), 2007
  • Figure 23: Sales Value Dynamics Of The Top 10 Pain Brands By Seven Major Market Revenues ($M), 2004-07
  • Figure 24: Us And 5eu Promotional Spend For The Top 10 Pain Market Brands, 2007
  • Figure 25: Seven Major Market Sales Revenues For 2007's Leading M1a - Nsaid Class Brands, 2004-07
  • Figure 26: Celebrex Seven Major Market Revenues ($M), 2007
  • Figure 27: Sevorane Seven Major Market Sales Revenue Versus Generics ($M), 2004-07
  • Figure 28: Seven Major Market Oxycodone Hcl Extended-Release Sales Value ($M) By Brand (Oxycontin) And Generics Versus Total Molecule Sales Volume (Sus), 2004-07
  • Figure 29: Seven Major Market Lyrica Sales Split By Sector - Pain Market Versus Total Other Sales, 2004-07
  • Figure 30: Sales Value Dynamics Of The Top 10 Pain Market Companies By Seven Major Market Revenues ($M), 2004-07